| Literature DB >> 33179015 |
Juliette Roels1,2, Morgan Thénoz1,2, Bronisława Szarzyńska3, Mattias Landfors4, Stien De Coninck1,2, Lisa Demoen1,2, Lien Provez1,2, Anna Kuchmiy2,5, Steven Strubbe5, Lindy Reunes1,2, Tim Pieters1,2, Filip Matthijssens1,2, Wouter Van Loocke1,2, Büşra Erarslan-Uysal6,7, Paulina Richter-Pechańska6,7, Ken Declerck8, Tim Lammens2,9, Barbara De Moerloose2,9, Dieter Deforce10, Filip Van Nieuwerburgh10, Laurence C Cheung11,12, Rishi S Kotecha11,12, Marc R Mansour13, Bart Ghesquière14, Guy Van Camp15, Wim Vanden Berghe8, Jerzy R Kowalczyk16, Tomasz Szczepański17, Utpal P Davé18, Andreas E Kulozik6,7, Steven Goossens1,2,5, David J Curtis19, Tom Taghon5, Małgorzata Dawidowska3, Sofie Degerman4,20, Pieter Van Vlierberghe21,2.
Abstract
Cancer cells display DNA hypermethylation at specific CpG islands in comparison to their normal healthy counterparts, but the mechanism that drives this so-called CpG island methylator phenotype (CIMP) remains poorly understood. Here, we show that CpG island methylation in human T-cell acute lymphoblastic leukemia (T-ALL) mainly occurs at promoters of Polycomb Repressor Complex 2 (PRC2) target genes that are not expressed in normal or malignant T-cells and which display a reciprocal association with H3K27me3 binding. In addition, we revealed that this aberrant methylation profile reflects the epigenetic history of T-ALL and is established already in pre-leukemic, self-renewing thymocytes that precede T-ALL development. Finally, we unexpectedly uncover that this age-related CpG island hypermethylation signature in T-ALL is completely resistant to the FDA-approved hypomethylating agent Decitabine. Altogether, we here provide conceptual evidence for the involvement of a pre-leukemic phase characterized by self-renewing thymocytes in the pathogenesis of human T-ALL.Entities:
Keywords: DNA methylation; Decitabine; T-ALL; aging; self-renewing thymocytes
Mesh:
Year: 2020 PMID: 33179015 PMCID: PMC7116343 DOI: 10.1158/2643-3230.BCD-20-0059
Source DB: PubMed Journal: Blood Cancer Discov ISSN: 2643-3230